BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

OvaScience Rakes In $37 Million Series B Financing


4/4/2012 7:05:13 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- OvaScience™, a fertility company focused on the discovery, development and commercialization of novel treatments for infertility, today announced that it has completed a $37 million Series B financing. The financing was led by General Catalyst. Existing investors, Bessemer Venture Partners and Longwood Fund, were joined by new, top-tier investors BBT Capital Management Advisors, LLC, Cycad Group, Hunt BioVentures, RA Capital and a large, global institutional investor, among others. In conjunction with this financing, John Simon, managing director of General Catalyst, has joined the OvaScience board of directors. Leerink Swann LLC acted as lead placement agent for the offering.

OvaScience plans to use the proceeds from the financing to support the development and commercialization of its fertility treatment approaches based on the egg precursor cell discoveries of OvaScience co-founder Jonathan Tilly, Ph.D., director of the Vincent Center for Reproductive Biology, chief of research for Massachusetts General Hospital (MGH) Vincent Department of Obstetrics and Gynecology, and professor, Department of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School (HMS). OvaScience holds an exclusive license from MGH to an issued U.S. patent and various patent applications related to Dr. Tilly’s egg precursor cell discoveries.

“Under the leadership of its world-class management and scientific teams, OvaScience has great potential to develop and commercialize new fertility treatment options for women,” said John Simon, managing director of General Catalyst. “OvaScience is rapidly advancing its patented fertility technology aimed at improving fertility outcomes, and we’re pleased to be part of a company that has a unique and differentiated approach in an area with a clear, unmet need.”

“OvaScience is focused on improving the success rates of fertility treatment options currently available for women,” said Michelle Dipp, M.D., Ph.D., chief executive officer of OvaScience. “As a result of this financing, the company expects to be able to advance its pipeline of fertility treatment approaches.”

About OvaScience

OvaScience is a privately-held fertility company focused on the discovery, development and commercialization of novel treatments for infertility. OvaScience is working to improve the treatment of female infertility based on patented technology exclusively licensed from Massachusetts General Hospital. The company's team of scientists, physicians and advisers are recognized leaders in the field of reproductive medicine. For more information, please visit the company’s website at www.ovascience.com.

Contact:

Pure Communications, Inc.

Dan Budwick, 973-271-6085


Read at BioSpace.com
Read at Boston Globe
Read at Xconomy
Read at Mass High Tech

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->